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Insulin resistance (IR), diabetes mellitus (DM), sarcopenia, and cognitive dysfunction are
thought to be mutually associated. We conducted a comprehensive assessment of
the relationships among IR, gait speed, hyperglycemia, and DM by cross-sectionally
analyzing the baseline data of an interventional study for cognitive preservation with
physical exercise (the TOyota Preventional Intervention for Cognitive decline and
Sarcopenia [TOPICS]). The participants (n = 444) were relatively healthy older individuals
who had mild cognitive impairment without dementia, and 61 of the participants had DM.
Slow gait speed and hyperglycemia were associated with cognitive dysfunction, mainly
in the executive function domain, whereas IR was associated with memory impairment.
The participants with DM had lower general cognition and executive function. Executive
dysfunction in the DM participants seemed to be partly explained by hyperglycemia
and/or slow gait speed. Our findings confirmed that IR, DM, sarcopenia, and cognitive
dysfunction are mutually associated in complex ways. Understanding the mechanisms
underlying these associations will lead to effective strategies to prevent and treat cognitive
dysfunction in older individuals.
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INTRODUCTION
Along with the increasingly aging populations in mainly developed countries, the number of
individuals with cognitive impairment has grown, leading to increases in medical expenses as well
as economic, physical, and psychological care-related burdens. There are no curative treatments for
cognitive dysfunction at this time, and the prevention of cognitive decline is a critical issue. Toward
this end, the identification of cognitive dysfunction risk factors (especially modifiable factors) is
urgently needed, and interventional trials for such risk factors would be warranted in order to
develop effective therapies.
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Many studies have shown that individuals with diabetes
mellitus (DM) have higher risks of dementia and cognitive
dysfunction (Koekkoek et al., 2015). The mechanism that
underlies DM-related cognitive dysfunction has not been fully
elucidated, but several hypotheses have been put forward
(Umegaki, 2014). Hyperglycemia is involved in the mechanism
of DM-associated cognitive dysfunction (Geijselaers et al., 2015),
as are other factors. Insulin resistance (IR) often leads to DM,
and patients with DM sometimes have cognitive dysfunction. The
results obtained in basic researches have suggested that systemic
IR may induce brain IR, or a deficiency of insulin effects in the
brain, which in turn may lead to the phosphorylation of tau
and the production of amyloid beta, and to Alzheimer disease
(AD)-related pathology (Bedse et al., 2015).
Muscle is a major target of insulin. Insulin binds to the
receptors on the muscle cells to transport blood glucose into
muscle (Ryder et al., 2001). In humans, muscle mass and
performance decrease with age, via a phenomenon known as
sarcopenia (Rosenberg, 1997). Sarcopenia is thus characterized
by a loss of muscle mass and strength (Cruz-Jentoft et al.,
2010). Because insulin has a catabolic effect, IR, which induces
impairment of protein synthesis in muscle, is suspected to be
involved in the development of sarcopenia (Umegaki, 2016). The
diagnosis of sarcopenia is based on the reduction of muscle mass,
but a loss in muscle power and a decline in physical performance
are also required for the diagnosis.
Gait speed is often used as an index of physical performance.
Several studies have reported that slower gait speed was
associated with cognitive dysfunction, mainly in the executive
function domain (Kearney et al., 2013; Demnitz et al., 2016),
and that slower gait speed is predictive of adverse health events
including dementia (Buchner et al., 1996; Guralnik et al., 2000).
The age-associated muscle mass reduction in sarcopenia has
also been reported to be associated with cognitive dysfunction
(Nourhashémi et al., 2002; Doi et al., 2014). Moreover, Burns
et al. (2010) reported that the age-associated reduction of lean
muscle mass is accelerated in AD and is associated with brain
atrophy and cognitive performance. Several studies have reported
that DM is associated with sarcopenia or lowmuscle performance
(Kearney et al., 2013; Demnitz et al., 2016). It may be speculated
that DM-related cognitive dysfunction is at least partly associated
with sarcopenia or low muscle performance, although there have
been few studies examining these potential associations.
DM is often associated with various metabolic alterations,
such as hyperglycemia and IR, as well as with indices of
sarcopenia, particularly low muscle performance (Umegaki,
2016; Zaslavsky et al., 2016). Both sarcopenia (Nourhashémi
et al., 2002; Doi et al., 2014) and IR (Umegaki et al., 2008; Ekblad
et al., 2015) have been associated with cognitive dysfunction
in older subjects. Therefore, the underlying mechanisms
of DM-related cognitive dysfunction may include or be
associated with IR and low muscle function. However, the
contributions of sarcopenia and IR to DM-related cognitive
dysfunction have not been studied extensively. Thus, while
it is anticipated that associations exist among IR, sarcopenia,
and cognitive dysfunction, few studies have comprehensively
assessed the associations these associations. In the present study
we investigated the associations among IR, sarcopenia, and
cognitive dysfunction to determine the contributions of IR and
declining physical performance to the development of DM-
related cognitive dysfunction.
METHODS
This was a randomized control trial to assess the effects of
different types of exercise (aerobic, resistance, or both) on
cognition in older subjects with a slight decline of memory
function based on the cross-sectional analysis of baseline data
from the TOyota Preventional Intervention for Cognitive decline
and Sarcopenia [TOPICS].
The study protocol was approved by our University’s Ethics
Committee (Graduate School of Medicine, Nagoya University;
approval no. 2014-0155-2) and registered with the University
Hospital Medical Information Network (UMIN) clinical trials
registry (no. UMIN000014437). Written informed consent was
obtained from all participants prior to their inclusion in the
study.
Participants
Participants were screened with the use of a questionnaire
comprised of 25 self-completed items (Arai and Satake, 2015),
including three items concerning subjective cognitive decline:
Q18, Do your family or friends point out your memory loss? (e.g.,
“You ask the same question over and over again”); Q19, Do you
make a call by looking up phone numbers?; and Q20, Do you find
yourself not knowing today’s date? Respondents who answered
yes to Q18 or Q20 or who answered no to Q19 were regarded
as being at high risk of cognitive decline (Maki et al., 2012).
The questionnaire was mailed to community-dwelling residents
aged 65–85 years in selected areas in the city of Toyota, Aichi,
Japan. Residents whomet the criteria for being at risk of cognitive
decline according to at least one of the three questionnaire items
described above were recruited via a mailing describing the
interventional study project.
The exclusion criteria were as follows: the subject (1) meets
clinical criteria for dementia, (2) has any disability with respect
to basic and instrumental activities of daily living (ADLs), (3)
requires support or care from the Japanese public long-term
care insurance system, (4) has a Mini-Mental State Examination
(MMSE) score ≤19, (5) has severe visual impairment, (6)
has been diagnosed with a neurodegenerative disease (e.g.,
Parkinson’s disease), (7) has medical conditions for which
exercise is contraindicated, (8) has a psychiatric disease (i.e.,
major depressive disorder), or (9) has a history of serious
cardiovascular, musculoskeletal, respiratory, or cerebrovascular
disease or other severe health issue.
DM was defined as a self-report of diagnosed DM, current use
of antidiabetic medication, fasting plasma glucose ≥126 mg/dl,
or HbA1c ≥6.5%. We excluded fasting blood glucose >140
mg/dl from the present analysis because it is not suitable for
the assessment of IR in these subjects (Wallace et al., 2004) with
homeostatic model assessment-insulin resistance (HOMA-IR;
Matthews et al., 1985).
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Measurements
A battery of neuropsychological assessments were performed by
a group of well-trained clinical psychologists, speech therapists,
and occupational therapists. Each score was rechecked by a single
neuropsychologist who was blinded regarding the other data
associated with the participants. The following tests were used.
To assess memory, we used the Logical Memory II subtest of
the WMS-R (Guo et al., 2009; Aisen et al., 2010); the MSE for
general cognitive ability (Folstein et al., 1975); and the Logical
Memory I subtests and Visual Reproduction I and II subtests
of the WMS-R (Wechsler, 1987). For verbal fluency, we used
the category fluency (animal naming) test and the letter fluency
test. For working memory, we used the Digit Span (forward
and backward) subtest and Visual Memory Span (forward and
backward) subtest of the WMS-R for working memory. Finally,
to assess processing speed, we used the Digit Symbol subtest of
the Wechsler Adult Intelligence Scale-III (WAIS-III; Wechsler,
1997); and the Trail Making Test parts A and B (Spreen and
Strauss, 1998).
Physical Function
We measured grip strength in the dominant hand of each
participant with the use of a portable grip strength dynamometer
(GRIP-D; Takei, Ltd., Niigata, Japan). Gait speed was assessed
during normal walking, with the participant instructed to walk
at his or her preferred speed (Doi et al., 2014).
Body Composition
We used a bioelectrical impedance data acquisition system
(Inbody 430; Biospace Co., Seoul, Korea) to perform the
bioelectrical impedance analyses. This system uses electrical
current at three frequencies (5, 50, 250 kHz) to directly measure
the amounts of extracellular and intracellular water in the human
body. Using segmental body composition and muscle mass, each
participant’s appendicular skeletal muscle mass was determined
and retained for further analysis. The skeletal muscle mass index
(SMI) was calculated by dividing the participant’s muscle mass by
his or her height in meters squared (kg/m2).
Blood Markers
A blood sample was obtained after the participant had fasted for
≥12 h. Serum samples were analyzed for total cholesterol, high-
density lipoprotein cholesterol, triglyceride, glucose, glycosylated
hemoglobin (HbA1c), and insulin. The apolipoprotein E (apoE)
genotypes were classified into e2/e2, e2/e3, e3/e3, e2/e4, e3/e4,
and e4/e4 based on the immunoblot technique using isoelectric
focusing. We obtained the blood samples in the morning
(between 9:30 a.m. and 12:00 p.m.). Insulin resistance was
assessed by HOMA-IR (Matthews et al., 1985).
Statistical Analysis
Student’s t-test was used for the comparison of continuous
variables. The distribution of frequencies for categorical variables
was analyzed with the Chi-square (χ2) test. We performed a
multiple regression analysis to investigate the associations of
cognitive performance and the factors of HOMA-IR values, gait
speed, HbA1c, and DM diagnosis with adjustment for age, sex,
number of school years, and apoE4 status. In the tests that
revealed a significant association with DM, we performed further
adjustment for any factors that were significantly associated with
cognition among HOMA-IR values, gait speed, and HbA1c.
RESULTS
Table 1 shows the background characteristics of the participants.
In both males and females, the body mass index (BMI) values
were significantly larger in the participants with DM. Among
the participants with DM (n = 61), the blood glucose, HbA1c,
insulin, and HOMAR-IR values were higher, but total cholesterol
(T-chol) and high-density lipoprotein cholesterol (HDL-chol)
were lower compared to those in the non-DM group (n= 383).
The body compositions and performance of the DM and non-
DM groups were comparable, with the exception that gait speed
was significantly lower (p= 0.024) in the DM group (Table 2).
In the cognitive assessment, the scores of MMSE, semantic
fluency, digit span, digit symbol, TMT-A, and TMT-B were
significantly lower in the DM group (Table 3).
The results of the multiple regression analysis (Table 4)
showed that HOMA-IR was associated with logical memory II
TABLE 1 | Background characteristics of the participants.
Total DM (−) DM (+) p-value
No. of participants 444 383 61
Age (yrs) 72.4 ± 4.7 72.4 ± 4.7 72.7 ± 4.8 0.651
Sex 52.3(232) 50.7(194) 62.3(38) 0.06
Education (yrs) 11.4 ± 2.4 11.5 ± 2.4 11.4 ± 2.8 0.905
BMI total (Kg/m2) 22.8 ± 2.9 22.6 ± 2.8 24.2 ± 3.2 <0.001
BMI male (Kg/m2) 23.2 ± 2.8 22.9 ± 2.5 24.4 ± 3.3 0.002
BMI female (Kg/m2) 22.5 ± 3.0 22.3 ± 3.0 23.8 ± 3.1 0.035
sBP (mmHg) 155.0 ± 20.2 154.9 ± 20.5 155.9 ± 18.4 0.711
dBP (mmHg) 79.2 ± 12.1 79.5 ± 12.1 77.3 ± 11.5 0.177
Tchol (mg/dl) 212.8 ± 36.9 216.6 ± 35.9 189.2 ± 34.7 <0.001
HDL chol (mg/dl) 66.5 ± 17.6 67.5 ± 17.3 60.3 ± 18.3 0.003
TG (mg/dl) 108.2 ± 57.0 107.5 ± 56.4 112.9 ± 61.3 0.489
FBS (mg/dl) 99.4 ± 12.5 97.1 ± 10.3 114.3 ± 14.6 <0.001
HbA1c (%) 5.8 ± 0.5 5.7 ± 0.3 6.6 ± 0.5 <0.001
Insulin (µU/ml) 5.6 ± 8.4 5.2 ± 5.8 8.0 ± 17.4 0.017
BUN (mg/dl) 15.6 ± 4.3 15.5 ± 4.1 16.3 ± 5.3 0.151
sCr (mg/dl) 0.77 ± 0.23 0.76 ± 0.22 0.84 ± 0.30 0.009
Hb (g/dl) 13.9 ± 1.3 14.0 ± 1.3 13.7 ± 1.1 0.204
CRP(mg/dl) 122 ± 349 120 ± 354 131 ± 320 0.819
HOMA-IR 1.43 ± 2.55 1.29 ± 1.52 2.38 ± 5.74 0.002
ApoE4 carrier [%(N)] 20.5 (91) 21.4 (82) 14.8 (9) 0.305
The data are the mean ± SD. Student’s t-test and the χ2 test were used to study
the differences between the participants with DM and the non-DM participants. BMI,
body mass index; sBP, systolic blood pressure; dBP, diastolic blood pressure; Tcho,
total cholesterol; HDL chol, high-density lipid cholesterol; TG, triglyceride; FBS, fasting
blood glucose; HbA1c, glycated hemoglobin A1c; BUN, blood urea nitrogen; sCr, serum
creatinine; Hb, hemoglobin; CRP, C-reactive protein; HOMA-IR, homeostatic model
assessment-insulin resistance; ApoE, apolipoprotein E. In the DM group the values of
blood glucose, HbA1c, insulin, and HOMAR-IR were higher, but T-chol and HDL-chol
were lower compared to those in the non-DM group.
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TABLE 2 | Body compositions of the participants.
Total DM (−) DM (+) p-value
n = 444 n = 383 n = 61
SMI
Male 7.2 ± 0.6 7.1 ± 0.6 7.3 ± 0.6 0.118
Female 5.7 ± 0.6 5.7 ± 0.6 5.9 ± 0.7 0.160
APPENDICULAR MUSCLE MASS
Male 19.2 ± 2.4 19.1 ± 2.4 19.6 ± 2.2 0.201
Female 13.0 ± 1.8 12.9 ± 1.8 13.3 ± 20. 0.423
GRIP STRENGTH
Male 33.9 ± 5.6 34.0 ± 5.7 33.2 ± 5.1 0.441
Female 21.7 ± 4.1 21.9 ± 4.0 20.1 ± 5.1 0.053
GAIT SPEED
1.41 ± 0.21 1.42 ± 0.20 1.36 ± 0.21 0.024
The data are the mean ± SD. Student’s t-test and the χ2 test were used to study the
differences between the participants with DM and the non-DM participants. SMI, skeletal
muscle mass index. Gait speed was significantly lower in the DM group.
TABLE 3 | Cognitive function of the participants.
Total DM (−) DM (+) p-value
n = 444 n = 383 n = 61
MMSE 26.2 ± 2.7 26.6 ± 2.7 25.4 ± 2.4 0.022
Logical memory I 14.7 ± 6.3 14.7 ± 6.4 14.7 ± 6.2 0.991
Visual reproduction I 32.1 ± 6.1 32.2 ± 6.1 31.4 ± 6.0 0.342
Logical memory II 10.0 ± 6.2 10.1 ± 6.4 9.6 ± 5.3 0.569
Visual reproduction II 22.4 ± 10.0 22.5 ± 10.1 22.2 ± 9.4 0.874
Letter fluency 8.7 ± 3.4 8.7 ± 3.4 8.7 ± 3.5 0.972
Semantic fluency 16.2 ± 4.3 16.5 ± 4.4 14.8 ± 3.4 0.004
Digit span 11.1 ± 2.8 11.3 ± 2.8 10.4 ± 2.7 0.037
Digit symbol 11.1 ± 2.7 11.3 ± 2.6 10.1 ± 3.0 0.001
TMT-A 45.4 ± 16.3 44.7 ± 15.4 49.9 ± 20.1 0.020
TMT-B 127.3 ± 58.0 124.1 ± 55.3 147.9. ± 70.2 0.004
GDS-15 4.07 ± 2.86 4.02 ± 2.91 4.39 ± 2.72 0.347
The data are the mean ± SD. Student’s t-test and the χ2 test were used to study
the differences between the participants with DM and the non-DM participants. MMSE,
Mini-Mental State Examination; TMT, Trail Making Test; GDS-15, Geriatric Depression
Scale-15. The values of MMSE, semantic fluency, digit span, digit symbol, TMT-A, and
TMT-B were significantly lower in the DM group.
after adjustment for age, sex, school years, and apoE4 status.
Gait speed was associated with logical memory I, semantic
fluency, letter fluency, digit symbol, TMT-A, and TMT-B.
The participants’ HbA1c values were associated with semantic
fluency, digit symbol, TMT-A, and TMT-B. We also observed
that DMwas associated withMMSE, semantic fluency, digit span,
digit symbol, TMT-A, and TMT-B.
In the tests that revealed a significantly association with
DM, we performed further adjustment for any factors that were
significantly associated with cognition among HOMA-IR, gait
speed, and HbA1c. For semantic fluency, TMT-A, and TMT-B,
further adjustments for gait speed and HbA1c diminished the
statistical significance of DM. For the digit symbol test, further
adjustments for gait speed and HbA1c attenuated the statistical
significance of DM (Table 4).
DISCUSSION
Our participants with DM had comparable muscle mass but
significantly slower gait speed compared to those without
DM. Slow gait speed and hyperglycemia have been associated
with cognitive dysfunction, mainly in the executive function
domain, whereas IR is associated with memory impairment. The
participants with DM had lower general cognition and executive
function. The executive dysfunction in the DM group seemed to
be partly explained by hyperglycemia and/or slow gait speed.
DM has been reported to be a risk factor for lower muscle
performance (Volpato et al., 2012; Kalyani et al., 2013). Several
mechanisms are involved in DM-related sarcopenia (Umegaki,
2016). Although, muscle mass is not necessarily decreased in
DM, muscle performance is impaired in DM (Guerrero et al.,
2016). Our present finding that DM subjects had slower gait
speed agreed in part with these observations.
In the current study DM subjects had significantly lower
scores in general cognition, and in the executive function
domain; they also had significantly lower scores in MMSE,
semantic fluency, digit span, digit symbol, TMT-A, and TMT-
B. It has been established that older individuals with DM have
impaired cognition. In addition, a previousmeta-analysis showed
that executive dysfunction is common among individuals with
DM (Palta et al., 2014), and general cognition measured by the
MMSE was found to reduced in a DM group compared to the
non-DM controls (Mogi et al., 2004).
We also observed that lower gait speed was associated
with executive dysfunction. In fact, lower gait speed was
associated with lower performance in a wide range of tests
that measure executive function. Systematic reviews have
confirmed the association between lower gait speed and executive
dysfunction (Kearney et al., 2013; Demnitz et al., 2016),
although the mechanism underlying this association remains to
be elucidated. Because the design of our present investigation
was cross-sectional, the cause-result relationship is unclear.
However, several possible explanations for this relationship
can be suggested. Walking requires complex coordination of
the extremities, and thus executive dysfunction may slow the
gait speed through impairments of attention, judgment, and/or
coordination. Alternatively, impaired gait function may limit
social interactions and engagement in leisure activities—both of
which changes have been associated with cognitive decline—and
it may increase the risk of depression (Shankar et al., 2013). As
another possible explanation of the association between lower
gait speed and executive dysfunction, recent research has revealed
that muscle secretes several factors called myokines. Myokines
regulate the lipid and glucosemetabolism, and they are associated
with insulin resistance through the control of inflammation
(Eckardt et al., 2014).
Another hypothesis is that shared causes of brain deficits
may induce both executive dysfunction and slow gait speed.
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TABLE 4 | Results of a multiple regression analysis of the associations between neurocognitive assessments and HOMA-IR, gait speed, HbA1c, and DM.
HOMA-IR Gait speed HbA1c DM
MMSE −0.026 (0.577)
0.043 (0.377)
−0.034 (0.463)
−0.105 (0.022)
Logical memory 1 −0.024 (0.602)
0.104 (0.034)
−0.001 (0.983)
0.009 (0.847)
Logical memory 2 −0.091 (0.047)
0.088 (0.069)
−0.032 (0.492)
−0.017 (0.720)
Visual reproduction1 −0.015 (0.745)
0.028 (0.555)
−0.011 (0.809)
−0.047 (0.296)
Visual reproduction2 −0.063 (0.161)
−0.031 (0.509)
−0.012 (0.784)
−0.005 (0.915)
Semantic fluency −0.054 (0.260)
0.132 (0.008)
−0.168 (0.000)
−0.146 (0.002)
0.119 (0.017) −0.129 (0.031) 0.054 (0.370)
Letter fluency −0.067 (0.150)
0.108 (0.027)
−0.046 (0.325)
0.013 (0.771)
Digit symbol −0.063 (0.171)
0.225 (0.000)
−0.102 (0.027)
−0.149 (0.001)
0.211 (0.000) −0.022(0.702) −0.114 (0.047)
Digit span −0.063 (0.178)
0.095 (0.053)
−0.033 (0.473)
−0.095 (0.041)
Visual memory span −0.046 (0.318)
0.071 (0.143)
−0.027 (0.553)
−0.060 (0.194)
TMT-A 0.005 (0.913)
−0.167 (0.000)
(Continued)
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TABLE 4 | Continued
HOMA-IR Gait speed HbA1c DM
0.098 (0.031)
0.106 (0.019)
−0.159 (0.001) 0.053 (0.354) 0.054 (0.347)
TMT-B −0.121 (0.006)
−0.098 (0.032)
0.112 (0.010)
0.140 (0.001)
0.074 (0.099) −0.083 (0.065) 0.116 (0.037) 0.056 (0.308)
Standardized coefficients β (p-value) are expressed. Adjusted for age, sex, school years, and apoE 4 status. In the tests that revealed a significant association with DM, further adjustments
were made for any significantly associated factors among HOMA-IR, gait speed, and HbA1c. HOMA-IR values were associated with logical memory II. Gait speed was associated with
logical memory I, semantic fluency, letter fluency, digit symbol, TMT-A, and TMT-B. HbA1c values were associated with semantic fluency, digit symbol, TMT-A, and TMT-B. DM was
associated with MMSE, semantic fluency, digit span, digit symbol, TMT-A, and TMT-B. In the tests that revealed a significant association with DM, further adjustments were performed
for any significantly associated factors among HOMA-IR, gait speed, and HbA1c. For semantic fluency, TMT-A, and TMT-B, a further adjustment for gait speed and HbA1c diminished
the statistical significance of DM. For the digit symbol test, further adjustment for gait speed and HbA1c attenuated the statistical significance of DM.
Subcortical ischemic vascular diseases are very common in
older individuals and have been associated with both executive
dysfunction (Jokinen et al., 2009), and slow gait speed (Rosano
et al., 2005; Kreisel et al., 2013). A recent study also reported
that amyloid beta deposition was associated with slow gait
(Nadkarni et al., 2017). Alternatively, inflammation may be a
shared pathology in both cognitive and physical dysfunction.
Systemic insulin resistance has been suggested to be associated
with brain IR (Kullmann et al., 2012). Therefore, the association
between systemic IR and cognitive dysfunction may be due to
an impairment of insulin signaling in the brain. Insulin signaling
in the brain inhibits glycogen synthase kinase 3 (GSK-3), which
phosphorylates tau to induce neurofibrillary tangles (Kandimalla
et al., 2016). A deficiency of insulin effects in the brain is thought
to accelerate AD pathology. The first cognitive symptom in the
disease process of AD is memory loss. The association that
we observed between memory decline and IR in the present
study’s population partially agreed with the hypothesis that IR
accelerates AD-related pathology in the brain.
Our study also indicated that HbA1c is associated with the
results of several cognitive tests, mainly for executive function.
Blood glucose itself may contribute to the cognitive decline
in individuals with DM. HbA1c is a marker of the average
blood glucose level over a relatively short term, i.e., 1–3 months
(Parrinello and Selvin, 2014). High blood glucose may affect
cognition relatively quickly. Or, many individuals with DM may
tend to have a stable blood glucose status, and HbA1c at a certain
point may represent the blood glucose status over longer periods.
As shown in Table 4, DM was associated with impairment in
several neuropsychological assessments in the present analyses.
However, the statistical significance of the associations between
DM and lower scores in cognitive tests were diminished
(semantic fluency, TMT-A, TMT-B) or attenuated (Digit symbol)
by the adjustments for gait speed and/or HbA1c when these
parameters were also associated with cognitions. The cognitive
impairment (mainly in executive function) was associated with
physical performance or blood glucose levels, and these factors at
least partly explained the association between DM and cognitive
dysfunction, which may suggest that the underlying mechanisms
of DM-related cognitive dysfunction involve these factors—
i.e., low physical function measured by slow gait speed and
hyperglycemia represented by higher HbA1c.
An interventional study indicated that physical intervention
was more effective in individuals with DM compared to non-DM
subjects (Espeland et al., 2016). The current study was a baseline
analysis of an interventional study which was originally designed
to assess the contribution of physical exercise to cognitive
preservation with physical exercise. The results regarding the
effects of interventions in our cohort will be reported in the near
future.
A major limitation of the present study was its cross-sectional
design; because of this design, the cause-effect relationships were
unclear. In addition, we analyzed the baseline data obtained in
a randomized control trial with exercise intervention. Ideally,
it would have been helpful to determine whether physical
or metabolic improvement by exercise can lead to cognitive
improvement. Other limitations of the study include the fact that
the diagnosis of DM was based mainly on the participants’ self-
report. Finally, we did not fully account for medications that
could potentially affect IR, since this information was lacking in
the baseline database used.
All three factors that were significantly associated
with cognitions in the current study—IR, gait speed, and
hyperglycemia—are modifiable. Indeed, exercise may improve
all three factors. In addition, antidiabetic agents improve
hyperglycemia, and some medicines may improve IR. The above
three factors were differently associated with different cognitive
domains. A comprehensive approach to all three factors is
warranted.
In conclusion, we assessed the associations among IR,
hyperglycemia, DM, sarcopenia, and cognition. Our results
showed that DM subjects had lower cognitive function compared
to non-DM subjects. Among the factors assessed in the current
study, IR was associated with memory impairment, while slow
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gait speed and hyperglycemia were associated with a wide-
range of cognitive domains, but primarily executive function.
The significance of the association between DM and cognitive
dysfunction was attenuated upon adjustment for slow gait speed
and hyperglycemia, which may suggest the involvement of these
factors in the underlying mechanism of DM-related cognitive
dysfunction. Further clarification of the mechanisms underlying
these associations will contribute to the prevention of cognitive
decline in the elderly.
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